Are you testing for PD-L1 IHC expression in extensive stage small cell lung cancer who are planned to be treated with chemotherapy plus immunotherapy?

Topics: Thoracic Malignancies • Medical Oncology

Are there subsets of patients who will not benefit with addition of first line immunotherapy?

Answer from: Medical Oncologist at Community Practice

Based on trial approved chemo-immunotherapy for ES-SCLC, it is not a requirement. IMpower33 (Atezo) and Caspian trial (durva).

Related Questions